CNCR vs. ILDR ETF Comparison

Comparison of Loncar Cancer Immunotherapy ETF (CNCR) to First Trust Innovation Leaders ETF (ILDR)
CNCR

Loncar Cancer Immunotherapy ETF

CNCR Description

ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.

Grade (RS Rating)

Last Trade

$15.86

Average Daily Volume

44,815

Number of Holdings *

71

* may have additional holdings in another (foreign) market
ILDR

First Trust Innovation Leaders ETF

ILDR Description First Trust Innovation Leaders ETF is an exchange-traded fund incorporated in the USA. The investment seeks to provide capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus any borrowings for investment purposes) in common stock and depository receipts issued by U.S. and non-U.S. companies that may benefit from the development or application of scientific and technological innovation. The fund’s investments will be concentrated in the information technology sector, and therefore, may be concentrated in one or more industries within the information technology sector. The fund is non-diversified.

Grade (RS Rating)

Last Trade

$21.53

Average Daily Volume

5,225

Number of Holdings *

60

* may have additional holdings in another (foreign) market
Performance
Period CNCR ILDR
30 Days -0.06% -2.86%
60 Days -8.85% -3.04%
90 Days 8.50% 3.06%
12 Months 19.27% 36.53%
4 Overlapping Holdings
Symbol Grade Weight in CNCR Weight in ILDR Overlap
RCUS F 1.18% 0.53% 0.53%
REGN B 1.33% 1.67% 1.33%
REPL F 1.01% 0.36% 0.36%
SWTX D 1.23% 1.04% 1.04%
CNCR Overweight 67 Positions Relative to ILDR
Symbol Grade Weight
GERN B 2.87%
ACRV B 2.63%
ELVN B 2.13%
JANX A 1.79%
NUVB B 1.7%
CGEM A 1.57%
RVMD A 1.56%
HCM B 1.54%
TSVT D 1.51%
DAWN A 1.5%
BPMC A 1.48%
MRK B 1.48%
EXEL D 1.47%
LYEL C 1.46%
YMAB C 1.43%
MOR C 1.41%
BCYC C 1.39%
PGEN D 1.39%
INBX D 1.38%
ITOS C 1.38%
IMCR D 1.37%
MGNX D 1.37%
NRIX D 1.37%
IPHA D 1.36%
AURA D 1.34%
BNTX D 1.33%
RAPT F 1.32%
GMAB D 1.32%
MRUS C 1.32%
VOR F 1.32%
BMY F 1.31%
SDGR F 1.31%
SNDX D 1.29%
DCPH A 1.29%
ACET F 1.28%
TYRA C 1.27%
ERAS D 1.27%
GLUE D 1.26%
IDYA D 1.25%
KYMR D 1.25%
PRLD D 1.22%
FHTX D 1.21%
XNCR C 1.21%
STRO F 1.21%
KURA D 1.2%
IMTX D 1.19%
ZNTL F 1.17%
IOVA D 1.16%
KPTI F 1.14%
NUVL D 1.12%
DNA F 1.12%
IGMS C 1.1%
RLAY F 1.09%
ACLX D 1.07%
SMMT C 1.06%
AUTL F 1.04%
RXRX F 1.03%
ARVN D 1.02%
CRBU F 1.01%
LEGN F 0.96%
ALLO F 0.95%
BMEA F 0.9%
RPTX F 0.89%
FATE D 0.83%
MRSN D 0.81%
GNLX F 0.78%
IMRX F 0.73%
CNCR Underweight 56 Positions Relative to ILDR
Symbol Grade Weight
NVDA C -6.72%
GOOG A -6.27%
MSFT C -5.61%
AMZN A -4.88%
UBER D -3.4%
NOW D -3.36%
ORCL D -3.26%
AVGO D -2.74%
META D -2.35%
BMRN F -1.84%
V D -1.73%
ANET D -1.65%
MU B -1.6%
GTLS C -1.56%
WDAY D -1.56%
SHOP D -1.56%
TMO C -1.45%
VRTX D -1.41%
AVTR C -1.4%
TOST D -1.39%
PCTY D -1.36%
MRVL D -1.3%
TW B -1.3%
EMR D -1.23%
PSTG C -1.17%
NFLX D -1.17%
MDB F -1.16%
NOC B -1.14%
AVAV B -1.12%
ZS D -1.12%
PLTR D -1.11%
ALNY D -1.1%
CRWD D -1.09%
DT F -1.08%
PANW B -1.05%
DDOG C -1.02%
LHX A -1.01%
RMBS F -0.98%
ACN F -0.97%
AKAM F -0.95%
MIRM D -0.94%
ISRG C -0.88%
TTD B -0.86%
TEL C -0.83%
HALO D -0.81%
SQ D -0.79%
CFLT D -0.78%
FOLD F -0.77%
ALGN F -0.77%
CYBR D -0.75%
TSLA D -0.68%
DXCM D -0.62%
FLGT F -0.51%
GRAB B -0.5%
INTC F -0.45%
ZI C -0.38%
Compare ETFs